Also trades as: 0K16.L (LSE) · $vol 0M
EOLS NASDAQ
Evolus, Inc.
1W: -10.4%
1M: -21.2%
3M: +2.1%
YTD: +6.2%
1Y: +16.1%
3Y: -21.4%
5Y: -9.3%
$7.14
-0.55 (-7.15%)
Weekly Expected Move ±6.8%
$6
$7
$7
$8
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (42)
Evolus drops as FDA says Jeuveau Instagram post is misleading
Corient Private Wealth LP Purchases New Shares in Evolus, Inc. $EOLS
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
625,000 Shares in Evolus, Inc. $EOLS Purchased by AWH Capital L.P.
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
Evolus targets $450M-$500M revenue and 13%-15% adjusted EBITDA margin in 2028 while raising 2026 revenue outlook to $330M-$337M
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) Q1 2026 Earnings Transcript
Evolus (EOLS) Q2 2025 Earnings Call Transcript
Here are the major earnings after the close Monday
Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Earnings Scheduled For May 4, 2026
JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS
Telix Appoints David Gill as Non-Executive Director
Evolus, Inc. $EOLS Shares Sold by Boothbay Fund Management LLC
Why Evolus Stock Soared Today
Evolus posts record rally after Q4 beat
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus (EOLS) Q4 2025 Earnings Call Transcript
Evolus Q4 Earnings Summary & Key Takeaways
Evolus: Q4 Earnings Insights
Here are the major earnings after the close Tuesday
Earnings Scheduled For March 3, 2026
What to Expect from Evolus's Earnings
Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Consensus PT from Brokerages
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Frontier Capital Management Co. LLC Buys 457,533 Shares of Evolus, Inc. $EOLS
Brokerages Set Evolus, Inc. (NASDAQ:EOLS) Target Price at $21.25